gastroenteritis%20-%20viral
GASTROENTERITIS - VIRAL
Acute gastroenteritis is a diarrheal disease of rapid onset.
Viruses are one of the common causes of gastroenteritis.
Rotavirus, enteric adenovirus serotypes 40 and 41, astrovirus and calicivirus (eg "Norwalk-like" virus) are the established viral agents causing gastroenteritis.
Rotavirus is the most common pathogen causing diarrhea in patients 3-24 months old.
Patients <3 months old are protected by maternal rotavirus antibodies that are passed transplacentally and possibly by breastfeeding.
Transmission is through fecal-oral route.
Incubation period may vary from 1-10 days depending on the causative agent.

Prevention

  • Prevention of most cases of viral gastroenteritis depends on the use of safe and effective vaccines
  • Currently, 2 vaccines are available to prevent severe diarrhea caused by rotavirus infection
    • Several studies support that early vaccination simulate initial natural infection, thus preventing subsequent severe cases of rotavirus gastroenteritis
Human Rotavirus Vaccine
  • Contains live attenuated human rotavirus strain
  • Prevents gastroenteritis caused by the most common genotypes G1, G2, G3, G4 and G9
    • Efficacy has also been demonstrated against genotypes G8 (severe gastroenteritis) and G12 (any gastroenteritis) 
  • Based on a clinical study done in Asia, the vaccine showed a 100% protective efficacy against severe gastroenteritis during the 1st year of life with the efficacy sustained up to 3 years of age
  • Can be simultaneously administered with the following vaccines without affecting the immune responses and safety profiles of the administered vaccines:
    • Hepatitis B vaccine (HBV)
    • Inactivated polio vaccine (IPV)
    • Haemophilus influenzae type b vaccine (Hib)
    • Pneumococcal conjugate vaccine (PCV)
    • Meningococcal serogroup C conjugate vaccine 
    • Diphtheria-tetanus-acellular pertussis vaccine (DTPa/DTaP)
    • Diphtheria-tetanus-whole cell pertussis vaccine (DTPwithDTwP)
    • Hexavalent vaccines (DTPa-HBV-IPV/Hib)
  • Concomitant administration with oral polio vaccine (OPV) may slightly reduce the immune response to rotavirus vaccine; however, the clinical protection of rotavirus vaccine against severe gastroenteritis would not be affected
    • It is advised that 2 weeks should lapse between administration of the 2 vaccines
Pentavalent Rotavirus Vaccine
  • Contains live reassortant rotaviruses developed from human and bovine hosts
  • Prevents gastroenteritis caused by serotypes G1, G2, G3, G4 and G9
    • Efficacy in preventing any grade of gastroenteritis severity reached 72.5-74% based on 2 studies done from the time of completion of 3-dose regimen through the 1st rotavirus season after the vaccination
    • The 2 trials also showed that the vaccine has clinical efficacy of 98-100% in preventing severe cases
    • There is a 95.8 % reduction in hospitalizations for severe gastroenteritis during the 1st 2 years following the final dose
  • May be simultaneously administered with the following vaccines without affecting the immune responses of the administered vaccines: HBV, IPV, OPV, Hib, PCV, DTPa, meningococcal serogroup C conjugate vaccine and hexavalent vaccines
  • Concomitant administration with OPV may reduce the immune response to rotavirus vaccine; however, there is evidence that a high level of efficacy against severe gastroenteritis is maintained 
    • It is advised that 2 weeks should lapse between administration of the 2 vaccines
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 02 Oct 2019
Baseline body mass index (BMI) and, to a lesser extent, school socioeconomic status are associated with subsequent weight status in schoolchildren, according to a study. Lifestyle behaviours show a lower effect as compared with prior BMI, but children with a healthier lifestyle have a reduced risk of overweight and obesity at follow-up.
04 Sep 2019
The use of iron-fortified formula milk in infants between 6–12 months of age may lead to poorer cognitive outcomes, a recent study has shown.
Audrey Abella, 07 May 2019
Use of electronic vapour products (EVP), or vaping, has been associated with an increased likelihood of engaging in sexual and substance-use risk behaviours among US teenagers, according to data from the 2017 National Youth Risk Behaviour Survey presented at the Paediatric Academic Societies (PAS) 2019 Meeting.
Jairia Dela Cruz, 04 Sep 2019
Parenteral antibiotic therapy duration for bacteraemic urinary tract infection (UTI) in young infants may be safely shortened, according to a recent study showing that recurrence and readmission or emergency department revisitation rates are comparable between a ≤7-day and a longer therapy course.